Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antiretroviral agents.

Lawrence Siegel1, Roy M Gulick

  • 1Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, Box 566, 525 East 68th Street, New York, NY 10021, USA.

Current Infectious Disease Reports
|April 14, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A 48-week, Randomized Controlled Trial of Doravirine for Individuals with HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391).

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

HIV Infection and Long COVID: A RECOVER Program, Electronic Health Record-Based Cohort Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

PEP Rally: Updated HIV Nonoccupational Postexposure Prophylaxis Guidelines From the Centers for Disease Control and Prevention.

Annals of internal medicine·2025
Same author

Future options for long-acting HIV treatment and prevention.

Current opinion in HIV and AIDS·2024
Same author

National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned.

Annals of internal medicine·2024
Same author

Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial.

AIDS and behavior·2024

Newer antiretroviral drugs are in development to combat drug-resistant HIV and improve patient outcomes. These investigational compounds offer enhanced tolerability, convenience, and efficacy for HIV treatment.

Area of Science:

  • Virology
  • Infectious Diseases
  • Pharmacology

Background:

  • Significant progress has been made in HIV treatment with 22 approved antiretroviral drugs.
  • There remains a critical need for novel antiretroviral agents with improved safety, tolerability, and activity against resistant strains.

Purpose of the Study:

  • To review investigational antiretroviral compounds in clinical development.
  • To highlight promising new agents for the treatment of HIV-infected individuals.

Main Methods:

  • Review of current literature on antiretroviral drug development.
  • Focus on compounds that have advanced to clinical trials.

Main Results:

  • Development is ongoing for new agents in traditional antiretroviral classes.

Related Experiment Videos

  • Novel mechanistic classes, including entry, integrase, and maturation inhibitors, are under investigation.

    • Conclusions:

    • Investigational antiretroviral compounds show promise for advancing HIV therapy.
    • Future HIV treatment may benefit from a broader range of drugs with diverse mechanisms of action.